Skip to content
type1.science
Phase 2Not yet recruitingNCT07325201

Continuous ketone monitoring for safer sotagliflozin in T1D with CKD

HealthPartners phase 2 trial developing DKA risk mitigation for people with T1D and mild-to-moderate CKD starting SGLT1/2 inhibitor therapy, using continuous glucose and ketone reporting.

Primary endpoints

  • Change in percentage of time in ketone range >1.5 mmol/L
  • Number of diabetic ketoacidosis episodes

Results so far

No results posted yet.